v3.26.1
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Expense

The following table presents the Company’s segment expense for the three and six months ended June 30, 2026 and 2025:

 

Oncology Segment

 

 

Oncology Segment

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

(in thousands)

 

 

(in thousands)

 

Revenue

 

$

-

 

 

$

3,181

 

 

$

-

 

 

$

8,573

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

       vopimetostat direct program expenses - R&D

 

 

12,345

 

 

 

5,577

 

 

 

21,677

 

 

 

11,038

 

       TNG456 direct program expenses - R&D

 

 

2,451

 

 

 

1,646

 

 

 

4,515

 

 

 

2,970

 

       TNG260 direct program expenses* - R&D

 

 

1,343

 

 

 

1,809

 

 

 

3,351

 

 

 

3,539

 

       TNG961 direct program expenses** - R&D

 

 

59

 

 

 

1,572

 

 

 

467

 

 

 

3,793

 

       TNG908 direct program expenses*** - R&D

 

 

60

 

 

 

1,235

 

 

 

641

 

 

 

2,947

 

       Discovery direct program expenses - R&D

 

 

2,414

 

 

 

2,709

 

 

 

4,287

 

 

 

7,388

 

       Personnel-related expenses - R&D

 

 

13,981

 

 

 

12,834

 

 

 

26,911

 

 

 

26,684

 

       Facilities and other related expenses - R&D

 

 

4,546

 

 

 

5,425

 

 

 

8,885

 

 

 

10,890

 

       Other segment expenses (a)

 

 

18,142

 

 

 

9,227

 

 

 

30,122

 

 

 

18,053

 

Segment net loss

 

$

(55,341

)

 

$

(38,853

)

 

$

(100,856

)

 

$

(78,729

)

*In May 2026, the Company announced it would deprioritize future development and resources allocated to the Phase 1/2 TNG260 clinical trial given the limited clinical benefit demonstrated in patients.

**In May 2026, the Company announced it did not plan to further advance development of TNG961.

***In November 2024, the Company announced it stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 relate to previously enrolled patients and close-out clinical trial costs.

(a) Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.